Gene therapy for the treatment of cancer

被引:16
作者
Buchsbaum, DJ
Curiel, DT
机构
[1] Univ Alabama Birmingham, Dept Radiat Oncol, Birmingham, AL 35294 USA
[2] Univ Alabama Birmingham, Div Human Gene Therapy, Birmingham, AL 35294 USA
关键词
cancer gene therapy; viral vectors; nonviral vectors; mutation compensation; genetic immunopotentiation; molecular chemotherapy; inhibition of angiogenesis; replicative vector oncolysis; chemosensitization; and radiosensitization;
D O I
10.1089/108497801753131354
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The delineation of the molecular basis of neoplasia provides the possibility of specific intervention by gene therapy through the introduction of genetic material for therapeutic purposes. In this regard, several gene therapy approaches have been developed for the treatment of cancer: mutation compensation, genetic immunopotentiation, molecular chemotherapy, inhibition of angiogenesis, replicative vector oncolysis, and chemosensitization or radiosensitization. Clinical trials have been initiated to evaluate safety, toxicity, and efficacy of each of these approaches, based on promising preclinical results. Various limitations that have been identified include lack of in vivo selective tumor delivery of vectors, minimal expression of therapeutic genes, immune response against vectors, and normal tissue toxicity. Combined modality therapy with gene therapy and chemotherapy or radiation therapy has shown promising results. It is expected that as new therapeutic targets and approaches are identified, combined with advances in vector design, that gene therapy will play an increasing role in clinical cancer treatment.
引用
收藏
页码:275 / 288
页数:14
相关论文
共 86 条
[71]   Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: Results of a phase I clinical trial in malignant mesothelioma [J].
Sterman, DH ;
Treat, J ;
Litzky, LA ;
Amin, KM ;
Coonrod, L ;
Molnar-Kimber, K ;
Recio, A ;
Knox, L ;
Wilson, JM ;
Albelda, SM ;
Kaiser, LR .
HUMAN GENE THERAPY, 1998, 9 (07) :1083-1092
[72]  
Suzuki K, 2001, CLIN CANCER RES, V7, P120
[73]  
Suzuki S, 2001, CANCER RES, V61, P1276
[74]  
Tjuvajev JG, 1999, CANCER RES, V59, P5186
[75]   Viral shedding and biodistribution of G207, a multimutated, conditionally replicating herpes simplex virus type 1, after intracerebral inoculation in Aotus [J].
Todo, T ;
Feigenbaum, F ;
Rabkin, SD ;
Lakeman, F ;
Newsome, JT ;
Johnson, PA ;
Mitchell, E ;
Belliveau, D ;
Ostrove, JM ;
Martuza, RL .
MOLECULAR THERAPY, 2000, 2 (06) :588-595
[76]  
Viret C, 1997, Int Rev Immunol, V14, P193, DOI 10.3109/08830189709116852
[77]   How cancer arises [J].
Weinberg, RA .
SCIENTIFIC AMERICAN, 1996, 275 (03) :62-70
[78]  
Xiang J, 2000, J GENE MED, V2, P97, DOI 10.1002/(SICI)1521-2254(200003/04)2:2<97::AID-JGM99>3.0.CO
[79]  
2-S
[80]   Characterization of the cyclooxygenase-2 promoter in an adenoviral vector and its application for the mitigation of toxicity in suicide gene therapy of gastrointestinal cancers [J].
Yamamoto, M ;
Alemany, R ;
Adachi, Y ;
Grizzle, WE ;
Curiel, DT .
MOLECULAR THERAPY, 2001, 3 (03) :385-394